• +1-646-491-9876
    • +91-20-67278686

    Search

    Bone Fracture - Pipeline Review, H1 2017

    Bone Fracture - Pipeline Review, H1 2017

    • Report Code ID: RW0001709443
    • Category Pharmaceuticals
    • No. of Pages 107
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Bone Fracture - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H1 2017, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.

    Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

    Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Bone Fracture - Overview
    Bone Fracture - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Bone Fracture - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Bone Fracture - Companies Involved in Therapeutics Development
    American Gene Technologies International Inc
    Arcarios BV
    AstraZeneca Plc
    Biogenomics Ltd
    BiologicsMD Inc
    Biopharm GmbH
    Bone Therapeutics SA
    Cellmid Ltd
    Chrysalis BioTherapeutics Inc
    Entera Bio Ltd
    Escape Therapeutics Inc
    ethris GmbH
    Kuros Biosciences AG
    Novartis AG
    Pluristem Therapeutics Inc
    TissueGene Inc
    Viking Therapeutics Inc
    Bone Fracture - Drug Profiles
    ALLOB - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-2858 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bimagrumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMD-1221 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cannabidiol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cyndacel-M - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    denosumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dibotermin alfa biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Bone Fracture - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Bone Fracture - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KAL-436/9 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KUR-111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KUR-113 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LWnt-3a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OsteoStem - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLX-PAD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rusalatide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SPI-86 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Fracture Repair - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TG-B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VK-5211 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bone Fracture - Dormant Projects
    Bone Fracture - Discontinued Products
    Bone Fracture - Product Development Milestones
    Featured News & Press Releases
    Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
    Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
    Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
    Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody
    Jun 24, 2016: Cellmid: New Publication And Patent Application For Midkine Antibody
    May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
    Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the 'Clinical Applications of Stem Cells' Conference
    Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
    Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
    Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects
    Oct 09, 2015: Kuros Presents Results of Phase IIB Study with KUR-111 at the 2015 Orthopaedic Trauma Association Annual Meeting
    Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture
    Jul 14, 2015: Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM) , in Acute Hip Fracture
    Mar 23, 2015: Bone Therapeutics treats first patients in ALLOB Phase IIA spinal fusion trial
    Jan 19, 2015: Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB Phase I/IIA Delayed-Union Trial
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Bone Fracture, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Bone Fracture - Pipeline by American Gene Technologies International Inc, H1 2017
    Bone Fracture - Pipeline by Arcarios BV, H1 2017
    Bone Fracture - Pipeline by AstraZeneca Plc, H1 2017
    Bone Fracture - Pipeline by Biogenomics Ltd, H1 2017
    Bone Fracture - Pipeline by BiologicsMD Inc, H1 2017
    Bone Fracture - Pipeline by Biopharm GmbH, H1 2017
    Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2017
    Bone Fracture - Pipeline by Cellmid Ltd, H1 2017
    Bone Fracture - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
    Bone Fracture - Pipeline by Entera Bio Ltd, H1 2017
    Bone Fracture - Pipeline by Escape Therapeutics Inc, H1 2017
    Bone Fracture - Pipeline by ethris GmbH, H1 2017
    Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2017
    Bone Fracture - Pipeline by Novartis AG, H1 2017
    Bone Fracture - Pipeline by Pluristem Therapeutics Inc, H1 2017
    Bone Fracture - Pipeline by TissueGene Inc, H1 2017
    Bone Fracture - Pipeline by Viking Therapeutics Inc, H1 2017
    Bone Fracture - Dormant Projects, H1 2017
    Bone Fracture - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Bone Fracture, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    American Gene Technologies International Inc
    Arcarios BV
    AstraZeneca Plc
    Biogenomics Ltd
    BiologicsMD Inc
    Biopharm GmbH
    Bone Therapeutics SA
    Cellmid Ltd
    Chrysalis BioTherapeutics Inc
    Entera Bio Ltd
    Escape Therapeutics Inc
    ethris GmbH
    Kuros Biosciences AG
    Novartis AG
    Pluristem Therapeutics Inc
    TissueGene Inc
    Viking Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//bone-fracture-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//bone-fracture-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//bone-fracture-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments